What is Comera Life Sciences Holdings EV-to-Revenue?
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Comera Life Sciences Holdings's enterprise value is $-0.70 Mil.
Comera Life Sciences Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $1.00 Mil. Therefore, Comera Life Sciences Holdings's EV-to-Revenue for today is -0.70.
The historical rank and industry rank for Comera Life Sciences Holdings's EV-to-Revenue or its related term are showing as below:
CMRA'
s EV-to-Revenue Range Over the Past 10 Years
Min: -1.11 Med: 11.52 Max: 516.57
Current: -0.7
During the past 3 years, the highest EV-to-Revenue of Comera Life Sciences Holdings was 516.57. The lowest was -1.11. And the median was 11.52.
CMRA's EV-to-Revenue is ranked better than 94.99% of 1038
companies
in the Biotechnology industry
Industry Median: 8.22
vs CMRA: -0.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Comera Life Sciences Holdings's EV-to-Revenue
For the Biotechnology subindustry, Comera Life Sciences Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Comera Life Sciences Holdings's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Comera Life Sciences Holdings's EV-to-Revenue falls into.
Comera Life Sciences Holdings EV-to-Revenue Calculation
Comera Life Sciences Holdings's current Enterprise Value is $-0.70 Mil.
Comera Life Sciences Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Comera Life Sciences Holdings (OTCPK:CMRA) EV-to-Revenue Explanation
Comera Life Sciences Holdings's share price for today is $0.02925.
Comera Life Sciences Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Comera Life Sciences Holdings EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Comera Life Sciences Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMRA has been successfully added to your 